NEW YORK (GenomeWeb News) – Asuragen has won $3.8 million in new stimulus funding from the National Institutes of Health, which it will use to advance its molecular diagnostics programs for cancer and genetic diseases, the company said today.

The company said that it received the funding through the Small Business Innovation Research and Small Business Technology Transfer programs, and the American Recovery and Reinvestment Act.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.